Skip to Main Content

Paper Details

Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia.
Mol Ther
2
2023
Author NameAffiliation
Mignon L LohSeattle Children's Hospital
  • 1 - 1

Datasets

Release 1.2